Company intelligence / Profile preview

Hebei Taihe Chunyu Biotechnology

Ownership: Private
Development stage: Other

Overview

Hebei Taihe Chunyu Biotechnology is a private Chinese biotech company developing next-generation CAR-T cell therapies targeting hematologic malignancies. Its lead assets include a CD7-specific CAR-T, a nanobody-based biepitope BCMA-targeting CAR-T, and bispecific CD19&CD20-targeted CAR-T cells. Early clinical results in relapsed/refractory patients with multiple myeloma and B-cell leukemia/lymphoma show promising safety and efficacy, including high response rates and manageable toxicity profiles when combined with pomalidomide. All programs are currently in Phase 1/2 trials.

Therapeutic areas: HematologyOncology
Modalities: CAR-T cell therapyNanobody-based CAR-T cell therapy
Industry: Biotech

Drug pipeline

5 assets

BAFF CAR-T

4 more assets in the full pipeline.

Partnerships

Wuhan Xiehe Hospital Tower / Wuhan Union Hospital

Beyond the preview

Go deeper on Hebei Taihe Chunyu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hebei Taihe Chunyu Biotechnology.